Akhil A Saji (@asajimd) 's Twitter Profile
Akhil A Saji

@asajimd

Urologist @ProvSwedish via @USC_Urology, @NYMCUrology, @HUMCUrology. Editor for @GUOncologyNow. Opinions are my own. RTs ≠ Endorsements. Try CPTcalc.net

ID: 762824760623529984

linkhttp://asaji.me calendar_today09-08-2016 01:36:10

316 Tweet

325 Followers

617 Following

Andrew Vickers (@vickersbiostats) 's Twitter Profile Photo

First single center RCT in the modern era to show a treatment effect on metastasis. Extended LND during radical prostatectomy superior to limited LND europeanurology.com/article/S0302-… Karim Touijer

Quinn Nelson (@snazzylabs) 's Twitter Profile Photo

The Mac mini’s 200W PSU is gorgeous. Has horizontally placed components that go through the PCB to reduce z-depth (we saw this first on Studio Display). Stunning.

The Mac mini’s 200W PSU is gorgeous. Has horizontally placed components that go through the PCB to reduce z-depth (we saw this first on Studio Display).

Stunning.
Anthony DiGiorgio, DO, MHA (@drdigiorgio) 's Twitter Profile Photo

There was a small yet significant change during the last Donald J. Trump administration led by Administrator Seema Verma that many outside healthcare may not know: the elimination of the Review of Systems (ROS) requirement. To understand why this mattered to physicians, here's some context:

GU Oncology Now (@guoncologynow) 's Twitter Profile Photo

📺 At the AUA Western Section meeting in Hawaii, GU Oncology Now section editor Dr. Akhil Saji and Amir Lebastchi, MD discuss the advancements and applications of focal therapy for #prostatecancer, exploring current standards and ideal patient selection: buff.ly/41BYri8

Wenhu Chen (@wenhuchen) 's Twitter Profile Photo

Another Microsoft paper revealing the size of GPT-4, GPT-o1 and Claude Sonnet. I'm not sure how trustworthy these numbers are, but they do make a lot of sense to me. Source: arxiv.org/pdf/2412.19260

Another Microsoft paper revealing the size of GPT-4, GPT-o1 and Claude Sonnet. 
I'm not sure how trustworthy these numbers are, but they do make a lot of sense to me.
Source: arxiv.org/pdf/2412.19260
Akhil A Saji (@asajimd) 's Twitter Profile Photo

If you have any interest in semiconductors, this article on the origins of its founder Morris Chang and the founding of TSMC is a must read open.substack.com/pub/constructi…

Rogerio Huang (@urorogerio) 's Twitter Profile Photo

New third gen sp instruments are a dramatic improvement. Extended range ability going to be a game changer Sp nephrectomy via low anterior access. Akhil A Saji, MD

Rogerio Huang (@urorogerio) 's Twitter Profile Photo

sp extraperitoneal RALP with extended range instruments. Extra grip and retraction on force bipolar and cardiere made posterior dissection and nerve sparing much easier. Suturing also felt much more natural Akhil A Saji, MD

Akhil A Saji (@asajimd) 's Twitter Profile Photo

LAA SP Partial Nephrectomy w Gen3 instruments🎥 Resection: Gen3✂️= tumor resection w/ greater ROM Renorrhaphy: L ✋🏽: Gen1 driver = limited strength & ROM R ✋🏽: NEW Gen3 driver = greater strength & ROM Gen3 = partials just like on Xi 🥂 Rogerio Huang Mickey Bindra Intuitive

𝙍𝙞𝙘𝙘𝙖𝙧𝙙𝙤 𝘽𝙚𝙧𝙩𝙤𝙡𝙤 MD PhD (@ricbertolo) 's Twitter Profile Photo

Published in Urology Gold Journal the report of the developement of an #AI-based #software created for autonomous fusion of #TRUS and #MRI images of the #prostate. Kudos to the team, particularly to f.cianflone who lead and discussed this project to graduate as a specialist in #urology,

Published in <a href="/urogoldjournal/">Urology Gold Journal</a> the report of the developement of an #AI-based #software created for autonomous fusion of #TRUS and #MRI images of the #prostate.

Kudos to the team, particularly to <a href="/Fcian_/">f.cianflone</a> who lead and discussed this project to graduate as a specialist in #urology,
Akhil A Saji (@asajimd) 's Twitter Profile Photo

Another Retro SP LAA partial example with Gen3 Instruments. Enhanced range of motion and articulation improve speed, efficacy and accessibility of partial nephrectomy. Get in and get out 🚀 Rogerio Huang Mickey Bindra

Vignesh Packiam, MD (@vigneshpackiam) 's Twitter Profile Photo

Just in time for AUA - A high-quality succinct review on contemporary intravesical therapy on NMIBC by the great Saum Ghodoussipour & all ⭐️ colleagues in European Urology Beautiful figures too! A valuable resource for patients & urologists Bladder Cancer Advocacy Network YUO pubmed.ncbi.nlm.nih.gov/40253283/

Just in time for AUA - A high-quality succinct review on contemporary intravesical therapy on NMIBC by the great <a href="/saumyg/">Saum Ghodoussipour</a> &amp; all ⭐️ colleagues in <a href="/EUplatinum/">European Urology</a>  

Beautiful figures too!

A valuable resource for patients &amp; urologists <a href="/BladderCancerUS/">Bladder Cancer Advocacy Network</a> <a href="/SUO_YUO/">YUO</a>

pubmed.ncbi.nlm.nih.gov/40253283/
Akhil A Saji (@asajimd) 's Twitter Profile Photo

Are there limits to SP LAA partial nephrectomy? What's the largest or most complex tumor you've managed with this approach? Sharing an example: a large, predominantly anterior upper pole tumor addressed via SP retro LAA. Rogerio Huang Mickey Bindra David Ambinder Mutahar Ahmed

Uromigos (@uromigos) 's Twitter Profile Photo

Joshua Meeks provides an amazing overview of the significant data emerging in the BCG-unresponsive NMIBC space, focusing on the CIS cohorts. We also discuss the recent ODAC decision on UGN-102 for lower risk disease which was recently FDA approved. spotifycreators-web.app.link/e/szAiuFvyaUb

<a href="/JoshMeeks/">Joshua Meeks</a> provides an amazing overview of the significant data emerging in the BCG-unresponsive NMIBC space, focusing on the CIS cohorts. We also discuss the recent ODAC decision on UGN-102 for lower risk disease which was recently FDA approved.

spotifycreators-web.app.link/e/szAiuFvyaUb